METASTATIC MALIGNANT SOLID NEOPLASM

This early-phase study is testing a personalized vaccine made from each patient's unique tumor mutations. The goal is to see if it is safe and can help the immune system fight advanced breast cancer, melanoma, and non-small cell lung cancer. About 25 adults whose cancers have spr…

This early-phase trial tests a personalized cell therapy for people with metastatic solid tumors that have a specific genetic change called KRAS G12V. Participants' own immune cells are collected, genetically modified to recognize and attack the cancer, and then infused back. The…

This early-stage trial tests two experimental drugs, peposertib and tuvusertib, together in people with advanced solid tumors that have spread or cannot be removed. The main goals are to find the safest dose and understand side effects. About 66 adults whose cancer has not respon…

This study tests an oral drug called larotrectinib in people aged 16 and older whose advanced solid tumors have too many copies of the NTRK gene. The drug works by blocking enzymes that help cancer cells grow. The main goal is to see how many patients' tumors shrink or disappear.

This study tests whether combining three drugs (axatilimab, retifanlimab, and paclitaxel) is safe and works against advanced or metastatic solid tumors. About 38 adults with tumors that have spread or come back will receive the combination. The goal is to find the best dose and s…

This early-stage trial tests the safety and best dose of combining two drugs—pidnarulex and trastuzumab deruxtecan—in people with advanced breast cancer or other solid tumors that have a protein called HER2. The study includes up to 36 adults whose cancer has spread, cannot be re…

This study is testing a drug called talazoparib in people with advanced solid tumors that have specific DNA repair gene mutations. The goal is to see if this PARP inhibitor can shrink tumors or slow their growth, even in patients who have already tried a similar drug. About 36 ad…

This study looks at two ways of giving focused radiation to people whose cancer has spread to the brain. One method gives all the radiation in a single session, while the other spreads it over several sessions. The goal is to see which approach better controls the tumors and caus…

This early-phase trial tests a drug called talazoparib (a PARP inhibitor) combined with one of three other drugs (palbociclib, axitinib, or crizotinib) in people with advanced or metastatic solid tumors. The goal is to find the safest dose and see if the combinations can help con…

This early-phase study tests a combination of two drugs, DS-8201a and olaparib, in people with advanced HER2-positive cancers that have spread or cannot be removed. The goal is to find the safest dose and see if the combination can shrink or stabilize tumors. About 55 adults whos…

This early-phase study tests the safety and best dose of TAK-243, a drug that blocks a key enzyme cancer cells need to grow. About 95 adults with advanced solid tumors or lymphoma who have tried other treatments will receive TAK-243. The goal is to find side effects and the right…

This early-stage trial tests an experimental pill called pidnarulex in 40 people with advanced solid tumors that have spread and stopped responding to standard treatments. The drug works by blocking a key enzyme that cancer cells need to grow and repair their DNA. Researchers wil…

This early-stage study tests two drugs together for people with HER2-positive stomach cancer or other solid tumors that have spread or can't be removed. The drugs, trastuzumab deruxtecan and azenosertib, aim to kill cancer cells more effectively. The main goals are to find the be…

This study tests whether three antibody-drug conjugates (ADCs) can shrink advanced or metastatic solid tumors that have high levels of specific proteins (Trop-2, nectin-4, or HER2). Participants will receive a drug matched to their tumor's protein profile. The goal is to see if t…

This early-stage trial tests a new drug called MTI-301 in about 42 adults with advanced solid cancers that have spread or not responded to standard treatments. The drug blocks an enzyme (SCD1) that some cancers need to grow. The main goals are to find a safe dose and check for si…

This early-phase trial is testing a procedure called PIPAC, which turns liquid chemotherapy into a fine mist and sprays it directly into the abdomen during a keyhole surgery. It is for people with ovarian, uterine, appendix, colorectal, or stomach cancer that has spread to the li…

This early-phase study tests the safety and best dose of two drugs—ZEN003694 and abemaciclib—given together to people with advanced breast cancer, NUT carcinoma, or other solid tumors that have spread or can't be removed by surgery. The goal is to see if the combination can shrin…

This early-stage trial tests the safety and best dose of a new drug (ZEN003694) combined with a standard chemotherapy (capecitabine) in adults with solid tumors that have spread or cannot be removed by surgery and have stopped responding to prior treatments. The goal is to find a…

This study tests a drug called durvalumab, which helps the immune system fight cancer, when given together with standard chemotherapy. It is for people with advanced solid tumors that have spread or cannot be removed by surgery. The goal is to see if the combination is safe and h…

This study tests a personalized vaccine made from a patient's own tumor proteins, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors (like breast, lung, or skin cancer). The goal is to see if the combination is safe and helps the immune syst…

This early-stage trial is testing a drug called CBX-12 in people with advanced solid tumors that have spread and stopped responding to at least one prior treatment. The drug works by entering cancer cells and damaging their DNA, which can kill the cells. The study aims to see how…

This study is testing whether two drugs, ZEN003694 and talazoparib, can shrink tumors in people with advanced solid cancers that have spread or cannot be removed. The trial enrolls 88 adults whose cancer has not responded to standard treatments. Researchers will also look at how …

This early-stage trial tests a drug called novobiocin in people with advanced solid tumors that have specific DNA repair gene mutations (like BRCA). Novobiocin blocks a protein that cancer cells use to fix their damaged DNA, causing them to die. The study aims to find the safest …

This study tests the drug pemetrexed in people with metastatic bladder cancer or other solid tumors that have certain gene mutations (MLL4, UTX, or MTAP). The drug works by blocking a nutrient cancer cells need to grow. Researchers want to see if it can shrink tumors in these pat…

This early-phase trial tests a new treatment for people with advanced melanoma or other solid tumors that have spread. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The goal is to find a safe dose and see if t…

This study tests a drug called avapritinib in people with advanced solid tumors that have spread and have specific gene changes (CKIT or PDGFRA mutations). The drug works by blocking enzymes that help cancer cells grow. The goal is to see if avapritinib can shrink or control thes…

This study tests a combination of two drugs, temozolomide and M1774, in adults with advanced solid tumors that have spread. The goal is to find the safest dose and see if the combo can shrink or slow tumor growth better than temozolomide alone. About 58 participants will take par…

This study tests a new drug called NBTXR3, which makes cancer cells more sensitive to radiation, combined with standard radiation and immunotherapy (anti-PD-1/L-1) for people with advanced solid tumors that have spread to the lungs or liver. The goal is to see if this combination…

This early-stage study tests a new chemotherapy drug, TR-002, in about 52 people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find the safest dose and check for side effects. The study also looks at whether the drug can shr…

This study compares two types of radiation therapy for people whose cancer has spread to the brain. One group gets a single high dose of radiation, while the other gets three smaller doses over several days. The goal is to see if the three-dose approach works better at controllin…

This early-stage study tests a new radiation method called BgRT for people whose cancer has spread to the bone and causes pain. The treatment uses live imaging to precisely target the tumor during a single session. Researchers want to see if it is safe and can reduce pain and the…

This study is testing whether getting immunotherapy in the morning or the afternoon makes it work better for people with advanced or metastatic solid tumors like lung, kidney, or skin cancer. Researchers think the body's internal clock might affect how the immune system responds.…

This study tests a parenting support program for 120 parents with advanced cancer and their spouses. The program aims to reduce parenting worries, improve family communication about cancer, and boost emotional well-being. Participants must have a child aged 4–16 living at home.

This study tests whether a psychedelic drug called psilocybin, given in a group retreat setting, can safely reduce anxiety and depression in people with incurable cancer. The drug is thought to help by resetting brain patterns that cause distress. The trial will enroll 18 adults …

This study tests whether adding cryoablation (freezing cancer cells) to standard radiation therapy provides better pain relief for people with cancer that has spread to the bones. About 40 adults with certain advanced cancers (like prostate, kidney, or colorectal) will be enrolle…

This study looks at how immune cells called T cells change in people with advanced melanoma, lung cancer, or other solid tumors during anti-PD-1 treatment. Researchers will measure specific markers in blood samples to see if they can predict whether the therapy is working or if r…

This study collects tissue samples from people with various advanced or early-stage cancers to train a diagnostic platform called Elephas. The goal is to see how accurately it can predict whether a patient will respond to immunotherapy or chemoimmunotherapy. About 324 participant…

This study screens people with advanced solid tumors to see if their cancer has specific genetic changes. Based on those results, they may be matched to a treatment trial that targets their tumor's unique genetics. The goal is to learn how well these targeted combinations work an…

This study collects tissue and blood samples from up to 5,000 cancer patients. The samples are used to create lab models, like cell lines and tumor grafts, to help scientists study cancer and test new drugs. It does not offer direct treatment but supports future research.

This early-phase trial studies how to best give arginine (a natural amino acid) alongside whole brain radiation for people whose cancer has spread to the brain. Researchers will compare oral and IV arginine to find the dose that reaches the highest blood levels. The goal is to le…

This study tests a new PET scan that tracks immune cells called CD8+ T cells, which help fight cancer. Ten adults with lymphoma or metastatic solid tumors will get the scan before and after radiation therapy. The goal is to see if radiation brings more immune cells to tumors, not…